OVARIAN CANCER RECURRENT
Clinical trials for OVARIAN CANCER RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CANCER RECURRENT trials appear
Sign up with your email to follow new studies for OVARIAN CANCER RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for ovarian cancer: can COM701 delay relapse?
Disease control Recruiting nowThis study tests an experimental drug called COM701 in people with ovarian cancer that came back after treatment but still responds to platinum chemotherapy. The goal is to see if COM701, given as a maintenance therapy every three weeks, can delay cancer progression longer than a…
Matched conditions: OVARIAN CANCER RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated May 17, 2026 02:21 UTC
-
Engineered immune cells take on tough ovarian cancer
Disease control Recruiting nowThis early-phase trial tests a one-time treatment called OPB-101 for people with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to ch…
Matched conditions: OVARIAN CANCER RECURRENT
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for recurrent ovarian cancer: targeted drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) for people with a fast-growing type of ovarian cancer that has returned after standard chemotherapy. R-DXd is an antibody drug conjugate that targets and destroys cancer cells. The study will check safety and how w…
Matched conditions: OVARIAN CANCER RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 12, 2026 13:43 UTC